 |
 Play Video: The Importance of Insider Buying
|
|
|
| Date | Insider | Price | Amount |
|---|
8-18-2023
Insider Buy |
Anthony P. Bihl III
Interim CEO |
$4.14
CAGR »
|
$165,076.04
39,885 shares |
8-14-2023
Insider Buy |
John A. Bartholdson
Director and >10% Owner |
$4.64
CAGR »
|
$301,687.70
65,022 shares |
8-10-2023
Insider Buy |
John A. Bartholdson
Director and >10% Owner |
$4.47
CAGR »
|
$500,419.14
111,848 shares |
6-13-2023
Insider Buy |
John A. Bartholdson
Director and >10% Owner |
$2.94
CAGR »
|
$1,338,164.38
455,725 shares |
5-23-2023
Insider Buy |
Anthony P. Bihl III
Interim CEO |
$2.33
CAGR »
|
$290,987.50
125,000 shares |
5-22-2023
Insider Buy |
John A. Bartholdson
Director |
$1.96
CAGR »
|
$2,573,128.08
1,315,673 shares |
2-11-2021
Insider Buy |
Alessandra Pavesio
SVP & Chief Science Officer |
$13.00
CAGR »
|
$13,000.00
1,000 shares |
2-11-2021
Insider Buy |
Gregory O. Anglum
SVP & General Counsel |
$13.00
CAGR »
|
$78,000.00
6,000 shares |
2-11-2021
Insider Buy |
Anthony D'adamio
SVP & General Counsel |
$13.00
CAGR »
|
$13,000.00
1,000 shares |
2-11-2021
Insider Buy |
John Nosenzo
Chief Commercial Officer |
$13.00
CAGR »
|
$6,500.00
500 shares |
Also See: Institutional Holders of BVS
Also See: SEC filings
Below we present the annualized performance delivered by Bioventus stock since 8-18-2023 (the date of the most recent
insider purchase). The performance of the investment from the time Bioventus insider buying occurred is the ultimate
test of whether insiders were right about BVS being a good buy.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
08/21/2023 |
|
| End date: |
04/26/2024 |
|
| Start price/share: |
$4.03 |
|
| End price/share: |
$3.98 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-1.12% |
|
| Annualized Gain: |
-1.64% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$9,888.00 |
|
| Years: |
0.68 |
|
Bioventus Insider Buying
This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.),
and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these
categories, but instead file their holdings quarterly on the latest form 13F filings.
While recent Bioventus insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).
Also See: Funds Holding BVS
|
|
Free BVS Email Alerts:
